IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to halt silent kidney damage
Disease control Recruiting nowThis study is testing whether adding an investigational oral drug called iptacopan to standard supportive care can reduce harmful immune activity and slow disease progression in adults with IgA nephropathy, a kidney disease. Researchers will compare kidney biopsies from 20 partic…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 04, 2026 03:06 UTC
-
New drug trial aims to protect Kids' kidneys from rare disease
Disease control Recruiting nowThis study is testing whether the drug ravulizumab can help children and teenagers (ages 2-18) with IgA nephropathy, a kidney disease where the immune system attacks the kidneys. Participants will receive the drug through an IV to see if it reduces protein in their urine and slow…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Major trial tests new drug to protect kidneys from silent disease
Disease control Recruiting nowThis study is testing whether the drug ravulizumab can slow the progression of IgA nephropathy (IgAN), a kidney disease that can lead to kidney failure. About 510 adults with IgAN who are at high risk of their disease getting worse will receive either the study drug or a placebo …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for kids with rare kidney diseases in 2-Year drug trial
Disease control Recruiting nowThis study is testing an oral medication called sparsentan in children aged 1 to 18 with specific rare kidney diseases. The main goal is to see if the drug is safe and can reduce harmful protein loss in urine over 108 weeks. Researchers will enroll about 67 children to monitor th…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC